Pfizer, BioNTech win bid to invalidate CureVac's UK COVID vaccine patents

Pfizer (PFE.N) and its German partner BioNTech (22UAy.DE)  on Tuesday won their attempt to invalidate two of rival CureVac's (5CV.DE) patents at London's High Court.
Pfizer and BioNTech had filed their lawsuit in September 2022 over patents relating to messenger RNA (mRNA) technology, which underpins Pfizer and BioNTech's COVID-19 vaccine.